Bavarian Nordic A/S (BVNRY) Analysts See $-0.16 EPS

August 13, 2018 - By Darrell Taylor

Bavarian Nordic A/S (OTCMKTS:BVNRY) Logo

Analysts expect Bavarian Nordic A/S (OTCMKTS:BVNRY) to report $-0.16 EPS on August, 24.They anticipate $0.23 EPS change or 328.57 % from last quarter’s $0.07 EPS. After having $-0.31 EPS previously, Bavarian Nordic A/S’s analysts see -48.39 % EPS growth. It closed at $9.42 lastly. It is down 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company has market cap of $922.18 million. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It has a 1178.68 P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.